List view / Grid view
Novartis’ radioligand therapy (RLT) is the first to demonstrate clinically…
Novartis’ radioligand therapy (RLT) is the first to demonstrate clinically meaningful benefit in a first line setting.
A pooled exploratory analysis shows Kisqali® plus endocrine therapy adds…
A pooled exploratory analysis shows Kisqali® plus endocrine therapy adds a year to overall survival of patients with aggressive form of breast cancer.
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus…
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months over fulvestrant alone.
US FDA have accepted Biologics License Application (BLA) for tislelizumab…
US FDA have accepted Biologics License Application (BLA) for tislelizumab for the treatment of oesophageal squamous cell carcinoma cancer.
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab…
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
